Xtant Medical Holdings, Inc.
Datakwaliteit: 100%
XTNT
NYSE
Manufacturing
Measuring & Analyzing Instruments
€ 0,48
▲
€ 0,01
(1,10%)
Marktkapitalisatie: 67,93 M
Prijs
€ 0,49
Marktkapitalisatie
67,93 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 24,77% annually over 5 years — strong growth
ROE of 10,06% — decent returns on equity
Debt/Equity of 0,35 — conservative balance sheet
Generating 10,16 M in free cash flow
P/E of 13,66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 10,56%
Groei
Revenue Growth (5Y)
24,77%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)14,21%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
10,06%
Boven sectorgemiddelde (-54,01%)
ROIC7,20%
Net Margin3,71%
Op. Margin5,44%
Veiligheid
Debt / Equity
0,35
Boven sectorgemiddelde (0,30)
Current Ratio2,21
Interest Coverage1,98
Waardering
PE (TTM|NTM)
13,66 | -24,00
Boven sectorgemiddelde (-1,49)
P/B Ratio1,35
EV/EBITDA5,99
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 13,7 | -1,5 |
| P/B | 1,4 | 1,6 |
| ROE % | 10,1 | -54,0 |
| Net Margin % | 3,7 | -41,5 |
| Rev Growth 5Y % | 24,8 | 1,8 |
| D/E | 0,4 | 0,3 |
Koersdoel Analisten
2 analisten
Buy
Huidig
€ 0,48
Koersdoel
€ 1,10
€ 1,00
€ 1,10
€ 1,20
Vooruitzicht
Forward K/W
-24,00
Forward WPA
-€ 0,02
Omzet Sch.
105,22 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
-€ 0,02
-€ 0,02 – -€ 0,02
|
105,22 M | 1 |
| FY2026 |
-€ 0,05
-€ 0,05 – -€ 0,05
|
96,20 M | 1 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
-€ 0,01
-€ 0,01 – -€ 0,01
|
24,57 M | 1 |
| 2026 Q1 |
-€ 0,02
-€ 0,02 – -€ 0,02
|
22,02 M | 1 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | € 0,00 | -€ 0,01 | 0,0% |
| Q32025 | € 0,00 | € 0,01 | 0,0% |
| Q22025 | -€ 0,02 | € 0,03 | +248,5% |
| Q12025 | -€ 0,01 | € 0,01 | +166,0% |
ETFs Holding This Stock
BRSIX
BRSIX
0,09% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 14,21% | Revenue Growth (3Y) | 21,11% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 174,50% |
| Revenue Growth (5Y) | 24,77% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 133,93 M | Net Income (TTM) | 4,97 M |
| ROE | 10,06% | ROA | 4,74% |
| Gross Margin | 62,92% | Operating Margin | 5,44% |
| Net Margin | 3,71% | Free Cash Flow (TTM) | 10,16 M |
| ROIC | 7,20% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,35 | Current Ratio | 2,21 |
| Interest Coverage | 1,98 | Asset Turnover | 1,28 |
| Working Capital | 42,83 M | Tangible Book Value | 36,02 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 13,66 | Forward P/E | -24,00 |
| P/B Ratio | 1,35 | P/S Ratio | 0,51 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 5,99 | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,65 | Fwd Earnings Yield | N/A |
| FCF Yield | 14,96% | ||
| Market Cap | 67,93 M | Enterprise Value | 74,94 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,03 | Revenue / Share | 0,96 |
| FCF / Share | 0,07 | OCF / Share | 0,09 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1,78% | FCF Conversion | 204,38% |
| SBC-Adj. FCF | 6,86 M | Growth Momentum | -10,56 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 133,93 M | 117,27 M | 91,30 M | 57,97 M | 55,26 M |
| Net Income | 4,97 M | -16,45 M | 660.000,0 | -8,49 M | -4,85 M |
| EPS (Diluted) | 0,03 | -0,12 | 0,01 | -0,09 | -0,06 |
| Gross Profit | 84,27 M | 68,22 M | 55,47 M | 32,14 M | 32,49 M |
| Operating Income | 7,28 M | -12,07 M | -10,16 M | -6,76 M | -3,85 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 2,10 M | 2,39 M | 1,34 M | 915.000,0 | 870.000,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | 5,22 M | 4,22 M | 3,17 M | 1,29 M | 1,33 M |
| Interest Expense | 3,67 M | 4,16 M | 2,94 M | 1,69 M | 995.000,0 |
| Income Tax | 2,03 M | 187.000,0 | -1,70 M | 69.000,0 | 296.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 94,15 M | 93,84 M | 92,61 M | 60,23 M | 54,69 M |
| Total Liabilities | 43,19 M | 50,87 M | 41,26 M | 26,06 M | 23,81 M |
| Shareholders' Equity | 50,95 M | 42,96 M | 51,35 M | 34,17 M | 30,88 M |
| Total Debt | 11,03 M | 22,04 M | 17,17 M | 9,69 M | 11,79 M |
| Cash & Equivalents | 17,05 M | 6,20 M | 5,72 M | 20,30 M | 18,24 M |
| Current Assets | 78,25 M | 67,12 M | 64,87 M | 49,32 M | 44,33 M |
| Current Liabilities | 29,48 M | 28,58 M | 22,99 M | 15,22 M | 11,08 M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Growth
Cash Flow Compounder
#86 of 350
#93 of 245
Recente Activiteit
Ingestapt
Cash Flow Compounder
Apr 12, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"XTNT","listing_kind":"stock","pathname":"/stocks/xtnt","exchange":"NYSE","country":"US"}}